157.49
price up icon2.00%   3.09
after-market Handel nachbörslich: 157.49
loading
Schlusskurs vom Vortag:
$154.40
Offen:
$154.01
24-Stunden-Volumen:
637.20K
Relative Volume:
0.42
Marktkapitalisierung:
$7.42B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
19.66
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+4.85%
1M Leistung:
+16.62%
6M Leistung:
-13.77%
1J Leistung:
-21.83%
1-Tages-Spanne:
Value
$152.84
$158.38
1-Wochen-Bereich:
Value
$148.41
$160.40
52-Wochen-Spanne:
Value
$91.86
$254.15

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
Firmenname
Charles River Laboratories International Inc
Name
Telefon
781-222-6000
Name
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Name
Mitarbeiter
20,100
Name
Twitter
@criverlabs
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CRL's Discussions on Twitter

Vergleichen Sie CRL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
157.49 7.42B 4.06B 413.08M 560.48M 8.01
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
427.76 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
202.50 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
542.71 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
120.66 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
164.65 27.64B 15.50B 1.33B 2.16B 7.34

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-23 Hochstufung Redburn Atlantic Neutral → Buy
2025-05-14 Hochstufung TD Cowen Hold → Buy
2025-05-08 Hochstufung Evercore ISI In-line → Outperform
2025-03-21 Herabstufung Goldman Buy → Neutral
2025-03-04 Hochstufung Citigroup Sell → Neutral
2025-03-03 Hochstufung Redburn Atlantic Sell → Neutral
2025-01-22 Herabstufung William Blair Outperform → Mkt Perform
2025-01-17 Herabstufung UBS Buy → Neutral
2024-11-18 Herabstufung CLSA Hold → Underperform
2024-11-07 Hochstufung CLSA Underperform → Hold
2024-10-23 Eingeleitet CLSA Underperform
2024-10-14 Eingeleitet Redburn Atlantic Sell
2024-10-07 Herabstufung Evercore ISI Outperform → In-line
2024-10-02 Herabstufung BofA Securities Buy → Neutral
2024-10-01 Herabstufung Citigroup Neutral → Sell
2024-08-08 Herabstufung JP Morgan Overweight → Neutral
2024-08-08 Herabstufung Robert W. Baird Outperform → Neutral
2024-06-28 Herabstufung Argus Buy → Hold
2024-06-07 Eingeleitet Mizuho Neutral
2024-06-06 Eingeleitet Goldman Buy
2024-02-15 Herabstufung Guggenheim Buy → Neutral
2023-09-13 Eingeleitet TD Cowen Market Perform
2023-07-10 Herabstufung Citigroup Buy → Neutral
2023-02-23 Hochstufung Guggenheim Neutral → Buy
2023-01-12 Herabstufung Jefferies Buy → Hold
2022-09-30 Hochstufung Jefferies Hold → Buy
2022-08-25 Eingeleitet Credit Suisse Outperform
2022-08-04 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-05-24 Eingeleitet Guggenheim Neutral
2022-04-25 Herabstufung Jefferies Buy → Hold
2022-04-07 Eingeleitet Stephens Overweight
2022-02-17 Bestätigt BofA Securities Buy
2022-02-17 Hochstufung Citigroup Neutral → Buy
2022-02-17 Bestätigt Deutsche Bank Buy
2022-02-17 Bestätigt Morgan Stanley Overweight
2022-02-17 Bestätigt UBS Buy
2021-08-05 Fortgesetzt Credit Suisse Neutral
2020-12-16 Herabstufung Citigroup Buy → Neutral
2020-09-10 Hochstufung Jefferies Hold → Buy
2020-07-01 Hochstufung BofA Securities Neutral → Buy
2020-05-13 Hochstufung UBS Neutral → Buy
2020-04-21 Herabstufung Jefferies Buy → Hold
2020-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-02 Eingeleitet Deutsche Bank Buy
2020-02-18 Hochstufung Wolfe Research Peer Perform → Outperform
2020-01-10 Hochstufung Goldman Neutral → Buy
2020-01-08 Eingeleitet Wells Fargo Overweight
2020-01-07 Eingeleitet Citigroup Buy
2019-10-18 Herabstufung BofA/Merrill Buy → Neutral
2019-06-10 Eingeleitet SVB Leerink Outperform
2019-04-30 Fortgesetzt Evercore ISI Outperform
2018-12-14 Eingeleitet Deutsche Bank Buy
2018-10-09 Eingeleitet UBS Neutral
2018-08-23 Hochstufung Raymond James Mkt Perform → Outperform
2018-07-17 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2018-06-15 Hochstufung KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 Hochstufung SunTrust Hold → Buy
Alle ansehen

Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten

pulisher
Jun 17, 2025

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Jun 17, 2025
pulisher
Jun 16, 2025

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment | CRL Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Do Wall Street Analysts Like Charles River Laboratories Stock? - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Global Viral Inactivation Market | Solvent Detergent & - openPR.com

Jun 16, 2025
pulisher
Jun 14, 2025

Charles River falls after projecting 2025 revenue drop - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Medical Device Testing Market Trends | Regulatory Compliance - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Charles River Laboratories credit outlook lowered to stable at S&P on weak 2025 guidance - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Charles River surges after Q1 beat, guidance raise - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Insiders At Charles River Laboratories International Sold US$2.8m In Stock, Alluding To Potential Weakness - simplywall.st

Jun 11, 2025
pulisher
Jun 11, 2025

Rhumbline Advisers Increases Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Jun 11, 2025
pulisher
Jun 09, 2025

Transcript : Charles River Laboratories International, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Polen U.S SMID Company Growth Strategy Sold Charles River Laboratories International (CRL) for More Attractive Opportunities - Insider Monkey

Jun 09, 2025
pulisher
Jun 06, 2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report? - Yahoo Finance

Jun 06, 2025
pulisher
Jun 05, 2025

Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - GlobeNewswire Inc.

Jun 05, 2025
pulisher
Jun 04, 2025

William Blair Remains a Hold on Charles River Labs (CRL) - The Globe and Mail

Jun 04, 2025
pulisher
Jun 04, 2025

Charles River at Jefferies Conference: Strategic Moves Amid Challenges By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Transcript : Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 10 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Charles River Laboratories To Present At Jefferies Global Conference; Webcast At 10:30 AM ET - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Cell Banking Outsourcing Market To Witness Substantial Growth, - openPR.com

Jun 04, 2025
pulisher
Jun 03, 2025

Charles River Stock May Gain From Extended CHDI Research Deal on HD - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

Charles River Laboratories International Inc (CRL) Shares Up 3.0 - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Charles River at William Blair Conference: Navigating Challenges with Innovation - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Charles River Laboratories To Present At William Blair Growth Stock Conference; Webcast At 11:00 AM - Nasdaq

Jun 03, 2025
pulisher
Jun 02, 2025

Charles River Laboratories to Present at William Blair and Jefferies Conferences - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Charles River Laboratories to Present at William Blair and Jeffe - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Charles River Laboratories to Present at William Blair and Jefferies Conferences | CRL Stock News - GuruFocus

Jun 02, 2025
pulisher
May 30, 2025

Charles River Laboratories International, Inc. (CRL): A Bull Case Theory - Insider Monkey

May 30, 2025
pulisher
May 28, 2025

Charles River Laboratories, CHDI Foundation Extend Collaboration - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research - BioSpace

May 28, 2025
pulisher
May 28, 2025

Charles River Laboratories International Extend Drug Discovery Partnership With CHDI Foundation - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Charles River Labs extends Huntington’s disease research pact By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Charles River (CRL) and CHDI Foundation Extend Partnership for H - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Charles River Labs extends Huntington’s disease research pact - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

Charles River (CRL) and CHDI Foundation Extend Partnership for Huntington's Drug Discovery | CRL Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Charles River Laboratories (CRL) and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research - StreetInsider

May 28, 2025
pulisher
May 25, 2025

Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT - MSN

May 25, 2025
pulisher
May 25, 2025

Should You Continue to Hold Charles River Stock in Your Portfolio? - MSN

May 25, 2025
pulisher
May 24, 2025

There's No Escaping Charles River Laboratories International, Inc.'s (NYSE:CRL) Muted Revenues Despite A 25% Share Price Rise - simplywall.st

May 24, 2025
pulisher
May 23, 2025

Charles River Laboratories International, Inc. (CRL) Extends CEO's Employment Agreement - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Charles River (CRL) Upgraded to Buy Amid Strategic Developments | CRL Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Redburn raises Charles River Labs to buy, cuts price target to $182 - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

Redburn raises Charles River Labs to buy, cuts price target to $182 By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Charles River Laboratories International CEO James C. Foster's Employment Extended Until February 2027SEC Filing - marketscreener.com

May 23, 2025

Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Charles River Laboratories International Inc-Aktie (CRL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
MASSARO GEORGE
Director
May 15 '25
Sale
137.57
140
19,260
5,575
MASSARO GEORGE
Director
May 14 '25
Sale
140.73
140
19,703
5,715
LaPlume Joseph W
EVP, Corp Strategy & Develop
May 13 '25
Sale
145.41
500
72,705
19,513
diagnostics_research DGX
$176.60
price down icon 1.52%
diagnostics_research WAT
$351.92
price down icon 1.43%
diagnostics_research LH
$260.00
price down icon 1.61%
$161.57
price up icon 0.53%
diagnostics_research MTD
$1,205.65
price up icon 0.03%
diagnostics_research IQV
$164.65
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):